Half Year 2026 Roche Holding AG Earnings Call Transcript

Jul 23, 2026 / 12:00 PM GMT

Transcript

Key Points

Positve

Roche Holding AG (RHHBF) reported a strong financial performance with a 10% increase in co-operating profit, outpacing sales growth of 6%.
The company achieved significant regulatory milestones, including five U.S. FDA priority reviews and two positive Phase III results, contributing to an 80% Phase III success rate.
Roche Holding AG (RHHBF) has a diversified portfolio with 16 blockbusters and maintains a strong market position in areas like diagnostics, hemophilia, ophthalmology, neurology, and oncology.
The diagnostics division grew by 3%, with notable growth in the pathology lab segment, driven by advanced staining and companion diagnostics.
Roche Holding AG (RHHBF) is making strategic acquisitions, such as PathAI and New York Therapeutics, to enhance its pipeline and diagnostics capabilities.

Negative

The company faced a negative impact from the flu season, which affected group results by more than $200 million.
Sales in China declined by 15% due to healthcare pricing reforms, impacting overall growth in the APAC region.
The U.S. market is experiencing low single-digit growth, with competitive pressures affecting certain product lines like Allisenza and Tecentric.
Roche Holding AG (RHHBF) anticipates increased tax rates in the second half of the year, which could impact net income.
The company is facing challenges in the biosimilar market, particularly in ophthalmology, where biosimilars are impacting the originator products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ROPC.S - Roche Holding AG
Half Year 2026 Roche Holding AG Earnings Call
Jul 23, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
That all participants are in listen-only mode during the call.

After the presentation, there will be a question-and-answer session. You are invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom.

In addition to that, you may also raise your virtual hand to address your questions verbally. For participants joining via phone, to raise your hand to your *9 on your phone style pad. When you then get selected to ask your questions, please follow the instructions from the phone and press *6 to unmute yourself.

One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.